LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Alvotech SA

Suletud

SektorTervishoid

10.65 1.72

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10.38

Max

10.76

Põhinäitajad

By Trading Economics

Sissetulek

177M

110M

Müük

-18M

133M

P/E

Sektori keskmine

30.311

51.198

Aktsiakasum

0.363

Kasumimarginaal

82.612

Töötajad

1,012

EBITDA

257M

137M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+166.67% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. aug 2025

Turustatistika

By TradingEconomics

Turukapital

291M

3.4B

Eelmine avamishind

8.93

Eelmine sulgemishind

10.65

Uudiste sentiment

By Acuity

9%

91%

8 / 380 Pingereas Healthcare

Alvotech SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. apr 2025, 14:54 UTC

Tulu

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Alvotech SA Prognoos

Hinnasiht

By TipRanks

166.67% tõus

12 kuu keskmine prognoos

Keskmine 28 USD  166.67%

Kõrge 28 USD

Madal 28 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Alvotech SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

8 / 380 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.